Mechanical properties and degradation of drug eluted bioresorbable vascular scaffolds prepared by three-dimensional printing technology

References

• Kim KH, Koo BK, Min HS, et al. Comparison of drug-eluting versus bare-metal stent implantation in ST-elevation myocardial infarction patients with renal insufficiency: results from the national registry in Korea. Int J Cardiol. 2012;154:71–77.
   PubMed Web of Science ®Google Scholar
• Choi HS, Jeong MH, Seo IK, et al. Very late stent thrombosis in a drug-eluting stent due to interruption of anti-platelet agents in patients with acute myocardial infarction and thrombocytosis. Korean Circ J. 2011;41:417–420.
   PubMed Web of Science ®Google Scholar
• Rhee SJ, Yun KH, Lee SR, et al. Drug-eluting stent thrombosis during perioperative period. Int Heart J. 2008;49:135–142.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Onuma Y, Ormiston J, et al. Bioresorbable scaffolds: rationale, current status, challenges, and future. Eur Heart J. 2014;35:765–776.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Farooq V, Kalesan B, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013;6:777–789.
   PubMed Web of Science ®Google Scholar
• Lesiak M, Araszkiewicz A. Leaving nothing behind": is the bioresorbable vascular scaffold a new hope for patients with coronary artery disease? PWKI. 2014;10:283–288.
   Google Scholar
• Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. EuroIntervention. 2009;5: F15–F22.
   PubMedGoogle Scholar
• Diletti R, Onuma Y, Farooq V, et al. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm. J Am Coll Cardiol. 2011;58:258–264.
   PubMed Web of Science ®Google Scholar
• Widmer MS, Gupta PK, Lu L, et al. Manufacture of porous biodegradable polymer conduits by an extrusion process for guided tissue regeneration. Biomaterials. 1998;19:1945–1955.
   PubMed Web of Science ®Google Scholar
• Schneck DJ. An outline cardiovascular structure and function. Biomedical Engineering Handbook Bd. 2010:1-1.
   Google Scholar
• Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet (London, England). 2009;373:897–910.
   PubMed Web of Science ®Google Scholar
• Zein I, Hutmacher DW, Tan KC, et al. Fused deposition modeling of novel scaffold architectures for tissue engineering applications. Biomaterials. 2002;23:1169–1185.
   PubMed Web of Science ®Google Scholar
• Moore SS, O’Sullivan KJ, Verdecchia F. Shrinking the supply chain for implantable coronary stent devices. Ann Biomed Eng. 2016;44:497–507.
   PubMed Web of Science ®Google Scholar
• Crump SS. Apparatus and method for creating three-dimensional objects. United States patent US 5121329A. 1992.
   Google Scholar
• Chan WA, Bini TB, Venkatraman SS, et al. Effect of radio-opaque filler on biodegradable stent properties. J Biomed Mater Res A. 2006;79:47–52.
   PubMedGoogle Scholar
• Ferdous J, Kolachalama VB, Kolandaivelu K, et al. Degree of bioresorbable vascular scaffold expansion modulates loss of essential function. Acta Biomater. 2015;26:195–204.
   PubMed Web of Science ®Google Scholar
• Alexis F. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)]. Polym Int 2005;54:36–46.
   Web of Science ®Google Scholar
• Ormiston JA, Webber B, Ubod B, et al. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition). EuroIntervention. 2015;11:60–67.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J. 2012;33:16–25b.
   PubMed Web of Science ®Google Scholar
• Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123:779–797.
   PubMed Web of Science ®Google Scholar
• Rieu R, Barragan P, Masson C, et al. Radial force of coronary stents: a comparative analysis. Cathet Cardiovasc Intervent. 1999;46:380–391.
   PubMed Web of Science ®Google Scholar
• Sotomi Y, Suwannasom P, Tenekecioglu E, et al. Differential aspects between cobalt-chromium everolimus drug-eluting stent and absorb everolimus bioresorbable vascular scaffold: from bench to clinical use. Expert Rev Cardiovasc Ther. 2015;13:1127–1145.
   PubMed Web of Science ®Google Scholar
• Garg S, Serruys P. Biodegradable stents and non-biodegradable stents. Minerva Cardioangiol. 2009;57:537–565.
   PubMedGoogle Scholar
• Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2010;6:447–453.
   PubMed Web of Science ®Google Scholar
• Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet (London, England). 2007;369:1869–1875.
   PubMed Web of Science ®Google Scholar
• Luo Q, Huang C, Wang S, et al. Comparative study of degradation behavior of bioresorbable cardiovascular scaffolds. Cardiovasc Eng Tech. 2015;6:71–79.
   PubMed Web of Science ®Google Scholar
• Onuma Y, Serruys PW, Gomez J, et al. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Cathet Cardiovasc Intervent. 2011;78:3–12.
   PubMed Web of Science ®Google Scholar
• van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690.
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Su SH, Sheng A, et al. In vitro hemocompatibility studies of drug-loaded poly-(L-lactic acid) fibers. Biomaterials. 2003;24:5191–5201.
   PubMed Web of Science ®Google Scholar
• Santis FD, Pantani R, Titomanlio G. Nucleation and crystallization kinetics of poly(lactic acid). Thermochim Acta. 2011;522:128–134.
   Web of Science ®Google Scholar
• Miyata T, Masuko T. Crystallization behaviour of poly (L-lactide). Polymer. 1998;39:5515–5521.
   Web of Science ®Google Scholar